Objectives: For investigating an influence on butylphthalide sodium chloride injection combined with edaravone dextromethorphan on neurological function, serum free radical levels, and serum inflammatory factor levels in sufferers having acute progressive cerebral infarction (APCI).
Methods: A cohort of 200 patients, afflicted by APCI and admitted to our healthcare institution between December 2018 through July 2023, were incorporated into this longitudinal prospective analysis. Employing a random number table methodology, the patient cohort was bifurcated into a control group ( = 100) and an observation group ( = 100). The control group is treated with butylphthalide sodium chloride injection and the study group is treated with edaravone dexborneol, based on the control group. The posttreatment curative efficacy on the two groups is recorded, and treatment of both the two groups is compared. Before and after neurological function indexes (NIHSS and BI), inflammatory factor indexes (hs-CRP, IL-8, and TNF-a), serum free radical levels (ROS, NO, and SOD), and contrasted between the two groups of treatment effect during therapy.
Results: Compared with the control (65%), the observation group exhibited a significantly higher effective rate of around 89%. In the observation group, the improvement in NIHSS, and Barthel index scores; inflammatory indexes including hs-CRP, IL-8, and TNF-a; and serum free radical levels including ROS, NO, and SOD in peripheral blood was better than the control group, with significant difference (all P<0.05).
Conclusion: The clinical efficacy of edaravone dexborneol combined with butylphthalide sodium chloride injection in the treatment of acute progressive cerebral infarction is precise, which can effectively reduce the level of inflammatory factors and serum free radicals in patients, improve the neurological function of patients, and reduce the damage of cerebral cells, and the safety is high.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693505 | PMC |
http://dx.doi.org/10.3389/fneur.2024.1415977 | DOI Listing |
HGG Adv
January 2025
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Inherited genetics represents an important contributor to risk of esophageal adenocarcinoma (EAC), and its precursor Barrett's esophagus (BE). Genome-wide association studies have identified ∼30 susceptibility variants for BE/EAC, yet genetic interactions remain unexamined. To address challenges in large-scale G×G scans, we combined knowledge-guided filtering and machine learning approaches, focusing on genes with (A) known/plausible links to BE/EAC pathogenesis (n=493) or (B) prior evidence of biological interactions (n=4,196).
View Article and Find Full Text PDFMed Sci Monit
January 2025
Department of Oral Implantology, The Affiliated Stomatology Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Province Key Laboratory of Oral Biomedicine, Jiangxi Province Clinical Research Center for Oral Disease, Nanchang, Jiangxi, China.
BACKGROUND This study included 32 patients with single missing teeth and alveolar bone defects and aimed to compare outcomes from guided bone regeneration with a gelatin/polylactic acid (GT/PLA) barrier membrane and a Guidor® bioresorbable matrix barrier dental membrane. MATERIAL AND METHODS A total of 32 participants were recruited in the clinical study, with single missing teeth and alveolar bone defects, requiring guided bone regeneration (32 missing teeth in total). They were randomly divided into the GT/PLA membrane group (experimental) and Guidor® membrane group (control) by the envelope method (n=16).
View Article and Find Full Text PDFRheumatol Ther
January 2025
Biosplice Therapeutics, Inc., 9360 Towne Centre Dr, San Diego, CA, 92121, USA.
Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.
Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.
Odontology
January 2025
Division of Oral Radiology, Faculdade São Leopoldo Mandic, Rua Dr. José Rocha Junqueira 13 Campinas, São Paulo, 13045-755, Brazil.
This study evaluated the association between dental infection and maxillary sinus pathology, and the influence of age, sex, type of tooth, root proximity to the sinus floor, the condition of the primary maxillary ostium, and the presence of an accessory maxillary ostium in this process. Computed Tomography scans were selected, and upper posterior teeth were evaluated for the presence of apical periodontitis (AP), bone loss with furcation involvement, and endoperiodontal lesion (EPL), subsequently, sinuses were evaluated for mucosal thickening (MT) and opacification of the maxillary sinus (OMS). Logistic regression models were constructed, and Chi-squared and Fisher's tests were applied.
View Article and Find Full Text PDFSci Rep
January 2025
PKUCare Lu'an Hospital, 046204, Shanxi, China.
Periodontitis, a common chronic inflammatory condition caused by bacteria, leads to loss of attachment, resorption of alveolar bone, and ultimately tooth loss. Therefore, reducing bacterial load and fostering alveolar bone regeneration are essential components in the treatment of periodontitis. In this study, we prepared smaller-sized Ag-Metal Organic Frameworks (Ag@MOF) and loaded with sodium alginate (Alg) hydrogel for periodontitis treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!